Compare NXDT & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXDT | ELDN |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.8M | 291.8M |
| IPO Year | 2006 | 2014 |
| Metric | NXDT | ELDN |
|---|---|---|
| Price | $5.22 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 127.6K | ★ 782.3K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,965,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $2.55 | $1.35 |
| 52 Week High | $5.95 | $4.60 |
| Indicator | NXDT | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 30.37 |
| Support Level | $4.35 | $1.96 |
| Resistance Level | $5.54 | $3.18 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 24.24 | 3.33 |
NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.